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LETTERS TO THE EDITOR
Risk Factors for Development of
Amiodarone-Induced Thyroid Dysfunction
The article of Albert et al. (I) on thyroid dysfunction during chronic
amiodarone treatment is of interest. The retrospective analysis of
our 87 patients (2) is in agreement with many of their findings,
especially the important observation that a lack of response of
thyrotropin to thyrotropin-releasing factor (TRH) does not nec-
essarily predict development of amiodarone-induced hyperthy-
roidism, which is in contrast to the observations reported by Staubli
and Studer (3).
The authors did not discuss the determination of circulating
thyroid autoantibodies (anti-thyroglobulin or anti-thyroid-micro-
somal antibodies, or both). Two of our five patients with amio-
darone-induced hypothyroidism had significant antibody titers,
Similar findings were reported by Amico et al. (4). Although sex
was not a significant risk factor in the series of Albert et al. (I),
59% of their female patients developed hypothyroidism in com-
parison with only 30% of their male patients, Wiersinga et al. (5)
reported an even higher difference: 58% of female in comparison
with 9% of male patients had amiodarone-induced hypothyroidism.
Because autoimmune thyroid disease is more prevalent in women
than in men it is tempting to suggest that preexisting thyroid disease
is a risk factor for amiodarone-induced hypothyroidism. The au-
thors do not give any data on pretreatment thyroid evaluation,
Did Albert et al. measure thyroid antibodies in their patients
and, if so, did the results agree with the suggestion of Amico et
al. (4) and our experience that positive titers tend to be a risk
factor for amiodarone-induced hypothyroidism.
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Reply
We did not measure thyroid autoantibodies and there may be two
cautionary notes regarding their use, First, thyroid antibodies may
not have been predictive of hyperthyroidism, and all five of our
717
hyperthyroid patients were male. Similarly, Mechlis et al. (l)
described a male predominance of hyperthyroidism in their patients
on long-term amiodarone therapy.
Second, there is the issue of how frequently to sample for
thyroid antibodies, Two recent articles have suggested that amio-
darone itself may induce antithyroid antibodies (2) or Tvcell-me-
diated abnormalities against the thyroid (3). Therefore, a single
baseline determination of thyroid antibodies may still not predict
future hypothyroidism.
We have recommended monitoring of thyroid function tests at
3 to 4 month intervals to recognize and treat the hypo- or hyper-
thyroidism at an early stage,
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Frequency and Significance of Ventricular
Arrhythmia in Patients With Reduced
Ejection Fraction «30%)
The abstract of Benhorin et al. (\) addresses a new frontier in
evaluating patients with heart failure. It does not give probability
values or state the method of analysis; however, the tables are
constructed for chi-square testing, so I assume that this was a
method used. One is perhaps less sure of a cause and effect relation
(that low ejection fraction causes increased arrhythmias) with this
type of analysis than one might be were the variables (ejection
fraction and arrhythmia incidence) ranked from high to low and
correlated, so that for any change in ejection fraction, it could be
determined if there was a corresponding change in arrhythmia
incidence. For purposes of analysis, this would treat the two vari-
ables as continuous and give us an answer in terms of a correlation
coefficient. This method has much to recommend it; it does not
